JPMorgan Chase & Co. Reaffirms Underweight Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “underweight” rating restated by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Tuesday,London Stock Exchange reports.

Separately, Berenberg Bank cut their target price on GSK from GBX 1,820 ($22.77) to GBX 1,600 ($20.02) and set a “buy” rating on the stock in a research report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.59).

GSK Stock Up 0.1 %

Shares of LON GSK traded up GBX 1.50 ($0.02) during midday trading on Tuesday, reaching GBX 1,351 ($16.90). 46,159,656 shares of the company’s stock were exchanged, compared to its average volume of 17,430,367. The stock has a market capitalization of £55.12 billion, a PE ratio of 1,195.58, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 52-week low of GBX 1,282.50 ($16.05) and a 52-week high of GBX 1,823.50 ($22.81). The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The business’s fifty day moving average price is GBX 1,358.38 and its two-hundred day moving average price is GBX 1,484.76.

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds purchased 1,500 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.45) per share, for a total transaction of £19,725 ($24,677.84). Insiders acquired a total of 8,658 shares of company stock worth $11,950,792 over the last 90 days. Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.